Taltz 5 year study

[Caroline]

I agree with Mataribot though, still doesn't sound like a great result.

I think this is an interesting subject. So I did some research and therefore I do not agree with Matarbot.

the research I found comes from a meta analysis done in 2018, found on pub med.

Quote: “ The drug survival for all biologics decreased with time, dropping from 66% at year 1 to 41% at year 4 for etanercept, from 69% to 47% for adalimumab, from 61% to 42% for infliximab, and from 82% to 56% for ustekinumab. Ustekinumab was associated with the highest drug survival in all and biologic-naïve subjects.”

So in fact a drug-survival rate of 2/3 = 66% Is quite average, even on the better side.

[mataribot]

I agree with Mataribot though, still doesn't sound like a great result.

I think this is an interesting subject. So I did some research and therefore I do not agree with Matarbot.

the research I found comes from a meta analysis done in 2018, found on pub med.

Quote: “ The drug survival for all biologics decreased with time, dropping from 66% at year 1 to 41% at year 4 for etanercept, from 69% to 47% for adalimumab, from 61% to 42% for infliximab, and from 82% to 56% for ustekinumab. Ustekinumab was associated with the highest drug survival in all and biologic-naïve subjects.”

So in fact a drug-survival rate of 2/3 = 66% Is quite average, even on the better side.

I am going to eat my words on this one and completely agree. A 2/3 survival rate is in line with other biological therapies and significantly better than older treatments. In conclusion, I think there is room for significant improvement in the long term viability of treatments.

[Caroline]

I agree with Mataribot though, still doesn't sound like a great result.

I think this is an interesting subject. So I did some research and therefore I do not agree with Matarbot.

the research I found comes from a meta analysis done in 2018, found on pub med.

Quote: “ The drug survival for all biologics decreased with time, dropping from 66% at year 1 to 41% at year 4 for etanercept, from 69% to 47% for adalimumab, from 61% to 42% for infliximab, and from 82% to 56% for ustekinumab. Ustekinumab was associated with the highest drug survival in all and biologic-naïve subjects.”

So in fact a drug-survival rate of 2/3 = 66% Is quite average, even on the better side.

I am going to eat my words on this one and completely agree. A 2/3 survival rate is in line with other biological therapies and significantly better than older treatments. In conclusion, I think there is room for significant improvement in the long term viability of treatments.

Now. I agree with you Mataribot

[Kat]

I agree there's room for improvement as average isn't good enough.